These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17704319)

  • 21. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
    Dawson P
    J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
    [No Abstract]   [Full Text] [Related]  

  • 22. Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks.
    Unruh C; Van Bavel N; Anikovskiy M; Prenner EJ
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33297578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrogenic systemic fibrosis: the need for accurate case reporting.
    Spinazzi A; Kirchin MA; Pirovano G
    J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
    [No Abstract]   [Full Text] [Related]  

  • 24. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?
    Nyman U; Elmståhl B; Leander P; Nilsson M; Golman K; Almén T
    Radiology; 2002 May; 223(2):311-8; discussion 328-9. PubMed ID: 11997530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New aromatic macrocyclic gadolinium chelates with enhanced relaxivity.
    Zhang X; Pillai R; Shukla R; Ranganathan RS; Tweedle M
    Invest Radiol; 1994 Jun; 29 Suppl 2():S69-70. PubMed ID: 7928275
    [No Abstract]   [Full Text] [Related]  

  • 26. Caution in Using Gadolinium-Based Contrast Agents in Interventional Pain Procedures.
    Benzon HT; Liu BP; Patel A; Benzon HA
    Anesth Analg; 2018 Dec; 127(6):1452-1456. PubMed ID: 30169406
    [No Abstract]   [Full Text] [Related]  

  • 27. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH
    J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
    Werner EJ; Datta A; Jocher CJ; Raymond KN
    Angew Chem Int Ed Engl; 2008; 47(45):8568-80. PubMed ID: 18825758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?
    Morcos SK
    Br J Radiol; 2007 Feb; 80(950):73-6. PubMed ID: 17392401
    [No Abstract]   [Full Text] [Related]  

  • 30. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 31. Alternatives to gadolinium-based metal chelates for magnetic resonance imaging.
    Viswanathan S; Kovacs Z; Green KN; Ratnakar SJ; Sherry AD
    Chem Rev; 2010 May; 110(5):2960-3018. PubMed ID: 20397688
    [No Abstract]   [Full Text] [Related]  

  • 32. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
    Idée JM; Port M; Medina C; Lancelot E; Fayoux E; Ballet S; Corot C
    Toxicology; 2008 Jun; 248(2-3):77-88. PubMed ID: 18440117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Contrast agents in MRT. Substance, effects, pharmacology and validity].
    Reimer P; Vosshenrich R
    Radiologe; 2004 Mar; 44(3):273-83. PubMed ID: 15287365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AAZTA-based bifunctional chelating agents for the synthesis of multimeric/dendrimeric MRI contrast agents.
    Gugliotta G; Botta M; Tei L
    Org Biomol Chem; 2010 Oct; 8(20):4569-74. PubMed ID: 20740241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Environment-sensitive and enzyme-sensitive MR contrast agents.
    Querol M; Bogdanov A
    Handb Exp Pharmacol; 2008; (185 Pt 2):37-57. PubMed ID: 18626598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reaction of gadolinium chelates with ozone and hydroxyl radicals.
    Cyris M; Knolle W; Richard J; Dopp E; von Sonntag C; Schmidt TC
    Environ Sci Technol; 2013 Sep; 47(17):9942-9. PubMed ID: 23888885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.